Perrigo (NYSE: PRGO) reported Q4 EPS of $0.93, $0.07 worse than the analyst estimate of $1.00. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.32 billion.

GUIDANCE:

Perrigo sees FY2021 EPS of $2.50-$2.70, may not compare versus the consensus of $4.21.

• For fiscal 2021, Perrigo Worldwide Consumer is committed to delivering 3% organic net sales growth, 5% adjusted operating income growth and 7% adjusted diluted EPS growth, in line with CPG peers that trade at much higher multiples. Based on a preliminary estimate of the accounting treatment to classify Rx as discontinued operations, translates to an adjusted diluted EPS range of $2.50 to $2.70.

For earnings history and earnings-related data on Perrigo (PRGO) click here.